Table 2.
Treatment characteristics at recurrence.
| n | % | |
|---|---|---|
| RT modality | ||
| 3DCRT | 15 | 36.6 |
| IMRT/Cyberknife | 26 | 63.4 |
| Re-RT total dose (Gy) | ||
| Median (range) | 50 | (30.0–60.0) |
| Re-RT dose per fraction (Gy) | ||
| Median (range) | 2 | (1.2–6.0) |
| Re-RT total dose in EQD2 (Gyab10) | ||
| Median (range) | 50.82 | (28.00–65.00) |
| Re-RT total dose in EQD2 (Gyab3) | ||
| Median (range) | 51.84 | (25.20–86.40) |
| Sum total dose (Gy) | ||
| Median (range) | 104 | (43.2–119.4) |
| Sum total dose in EQD2 (Gyab10) | ||
| Median (range) | 105.18 | (42.48–123.41) |
| Sum total dose in EQD2 (Gyab3) | ||
| Median (range) | 105.84 | (41.47–134.78) |
| Re-RT duration (days) | ||
| Median (range) | 36 | (13–69) |
| Re-RT completion of planned dose | ||
| No | 1 | 2.4 |
| Yes | 40 | 97.6 |
| Rest during re-RT | ||
| No | 36 | 87.8 |
| Yes | 5 | 12.2 |
| Concurrent chemotherapy | ||
| No | 20 | 48.8 |
| Yes | 21 | 51.2 |
RT, radiotherapy; 3DCRT, 3D conformal radiotherapy; IMRT, intensity-modulated radiotherapy.